ArticleJournal of clinical medicine research2019
Change in the Antimicrobial Resistance Profile of Extended-Spectrum β-Lactamase-Producing
Article in Journal of clinical medicine research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- The Evolving Microbiology and Antimicrobial Resistance in Peritonitis of Biliary Origin: An Evidence-Based Update of the Tokyo Guidelines (TG18) for Clinicians.Diagnostics (Basel, Switzerland) · 2025Review
- Antibiotic resistance profiles and risk factors of multidrug-resistant Escherichia coli in a large tertiary care hospital in a low- and middle-income country.Scientific reports · 2025Article
- Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula.Scientific reports · 2025Article
- Effects of Prospective Audit and Feedback in Patients with Extended-SpectrumMicroorganisms · 2024Article
- Antimicrobial Resistance Profile of Bacteria Causing Pediatric Infections at the University Teaching Hospital in Rwanda.The American journal of tropical medicine and hygiene · 2022Article
- Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- A Strategy for Hospital Pharmacists to Control Antimicrobial Resistance (AMR) in Japan.Antibiotics (Basel, Switzerland) · 2021Review
- Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system.Antimicrobial resistance and infection control · 2021Observational
- In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Infective Endocarditis Caused by Extended-Spectrum Beta-Lactamase-ProducingInfection and drug resistance · 2021Article
- Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model.Pharmaceutical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the trends and antimicrobial resistance profile of extended-spectrum β-lactamase-producing
methodsA total of 1,303
resultsThe proportion of ESBL-EC among all the
conclusionsOur findings indicate a changing antimicrobial resistance profile of ESBL-EC, particularly to fluoroquinolones. Determination of the prevalence and antimicrobial resistance of ESBL-EC will help physicians in selecting the initial empirical treatment for patients with ESBL-EC infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.